Join
Live feed
·
PRReleasevia Quantisnow
Navidea Biopharmaceuticals Inc. logo

Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering

ByQuantisnow·Wall Street's wire, on your screen.
NAVB· Navidea Biopharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NAVB (Navidea Biopharmaceuticals Inc.) and more on Quantisnow.